logo
Plus   Neg
Share
Email

Lilly, Rigel To Develop RIPK1 Inhibitors For Treatment Of Immunological & Neurodegenerative Diseases

Eli Lilly and Co. (LLY) and Rigel Pharmaceuticals Inc. (RIGL) said that they have collaborated to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 or RIPK1 inhibitor, for the potential treatment of immunological and neurodegenerative diseases.

Lilly said it will obtain an exclusive worldwide license to Rigel's RIPK1 inhibitors, including Rigel's Phase 2-ready molecule R552, in all indications.

As per the terms of the deal, Lilly will pay an upfront cash payment to Rigel of $125 million. Rigel may also be eligible to receive up to $835 million in potential development, regulatory, and commercial milestone payments, as well as tiered royalties ranging from the mid-single digit to high-teens that will vary depending upon Rigel's clinical development investment.

Lilly and Rigel will co-develop R552 at specified contribution levels. Lilly will be responsible for all costs of global commercialization for R552, and Rigel will have the right to co-commercialize R552 in the U.S.

Lilly will be solely responsible for all clinical development and commercialization of brain penetrating RIPK1 inhibitors in CNS indications.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Canada's Olymel S.E.C./L.P. has recalled around 6,804 pounds of ready-to-eat or RTE ham products for potential contamination with Salmonella Enteritidis, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. ViacomCBS Inc. announced plans to combine CBS News and the CBS Television Stations. The journalistic and business operations of both will be combined into one divisional and leadership structure. Neeraj Khemlani and Wendy McMahon were appointed as presidents and co-heads of the newly formed division, effective early next month. Retail major Target Corp. is recalling about 44,350 units of Cat & Jack Baby Heart Ears Rompers, citing choking risks to children, the U.S. Consumer Product Safety Commission said in a statement. The recall involves rompers sold in various sizes from newborn to 24 months. The rompers were manufactured in Vietnam, and sold at Target stores across the United States and online.
Follow RTT